Products
Amubarvimab/Romlusevimab | Brii Biosciences
Service description
Brii Biosciences’ monoclonal antibody combination therapy, BRII-196/BRII-198, is designed to neutralize SARS-CoV-2 and provide a treatment option for non-hospitalized COVID-19 patients at high risk of clinical progression to severe disease. It received approval from the NMPA in China.